7.89
Wave Life Sciences Ltd (WVE) 最新ニュース
Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Nasdaq
What is Leerink Partnrs’ Estimate for WVE Q1 Earnings? - Defense World
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha
WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia
Wave Life Sciences unveils Phase II data for DMD therapy, WVE-N531 - Yahoo Finance
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Yahoo Finance
Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com
Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online
Sector Update: Health Care Stocks Retreat Wednesday Afternoon - Marketscreener.com
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa
Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success - The Boston Globe
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN
Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia
Wave Life Sciences shares surge on positive DMD trial results - Investing.com
Wave Life Sciences reports progress in DMD treatment - Investing.com India
Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener
Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire
Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan
Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa
Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World
US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
How To Trade (WVE) - Stock Traders Daily
Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com
Mizuho maintains WAVE Life Sciences Outperform rating - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World
HC Wainwright Cuts Earnings Estimates for Wave Life Sciences - Defense World
Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst - Defense World
Wave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.com - Defense World
Wave Life Sciences CEO Paul Bolno sells shares worth $1.62 million - Investing.com Australia
Commit To Purchase Wave Life Sciences At $7.50, Earn 25.6% Annualized Using Options - Nasdaq
Wave Life Sciences (NASDAQ:WVE) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Set Expectations for WVE Q1 Earnings - Defense World
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com India
Wave Life Sciences’ Earnings Call Highlights Progress and Challenges - TipRanks
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript - MSN
Truist maintains Buy rating on WAVE Life Sciences stock, $36 target By Investing.com - Investing.com South Africa
RBC Trims Price Target on Wave Life Sciences to $14 From $15, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Rhumbline Advisers Buys 17,316 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ... By GuruFocus - Investing.com Canada
Y Intercept Hong Kong Ltd Sells 6,875 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Principal Financial Group Inc. Buys Shares of 248,645 Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: R - GuruFocus.com
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ... - Yahoo Finance
大文字化:
|
ボリューム (24 時間):